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(before treatment - 50,9±3,9; after two months- 42,7±4,6; t=3,1;
p=0,011), Womac pain scale (before treatment - 47,0±5,3; after
two months- 30,4±6,5; t=2,89; p=0,016). The constraint of move-
ments decreased (before treatment 47,4±5,1; after two months-
35,9±6,6; t=2,67; p=0,023), and index of everyday activity im-
proved (before treatment 50,0±6,1; after two months- 38,3±6,3;
t=2,25; p=0,048).
Conclusions: Theraﬂex-Advance is instrumental in rapid de-
crease of intensity of the pain syndrome (after two weeks) in
patients with knee osteoarthritis. Over a month after cessation
of preparation taking, positive effect remains: knee pain is sig-
niﬁcantly lower in comparison with indexes before treatment;
constraint index increases and index of everyday activity ag-
gravates. Herewith, the given indexes remain lower than before
treatment. The analgesic effect after taking Teraﬂex-Advance be-
comes noticeable after two months when it is followed by the
essential decrease of constraint index, improvement of index of
everyday activity. Quality of life signiﬁcantly improved in patients
of both groups.
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Purpose: Topical formulations of diclofenac have been devel-
oped to provide local analgesic and anti-inﬂammatory effects
with minimal systemic exposure. The primary objective of this
study was to determine the long-term safety of diclofenac sodium
gel 1% (DSG) in patients with osteoarthritis (OA) of the knee.
Methods: To evaluate long-term safety of DSG, we have pooled
947 DSG patients from 3 studies of primary knee OA: a multicen-
ter, open-label 12-month study treating 1 or 2 knees (n=578) and
two previously completed double-blind 3-month trials treating 1
knee (n=369). The dose was 4 g of DSG 4 times per day in
all studies. Safety was assessed by monitoring adverse events
(AEs), clinical laboratory evaluations, vital signs, and physical
examinations. Assessment of pain/stiffness/physical function in
the target knee was a secondary objective and was evaluated
with the use of the Western Ontario and McMaster Universities’
OA (WOMAC) index.
Results: A total of 583 patients were enrolled in the open-label
study, including 292 naïve patients and 291 who continued from
the two 3-month double-blind studies. Of these, 350 treated 1
knee, 228 treated 2 knees and 5 could not be documented. Half
the patients were treated for 6 to 12 months, a third treated
12 months. The 369 DSG-treated patients from the double-blind
studies who did not continue into the open-label study were also
added to the safety population (n=947). Of all treated patients,
67.8% experienced a treatment-emergent adverse event (TEAE)
(65.5% of 719 patients in the 1-knee group and 75.0% of 228
patients in the 2-knee group). The most common TEAE was
headache (17.6% of treated patients, 16.6% and 21.1% of the 1-
knee and 2-knee groups, respectively). Application-site dermatitis
was reported by 10.5% of treated patients, 9.0% and 14.9%
of the 1-knee and 2-knee groups, respectively. Other common
TEAEs were arthralgia, back pain, and nasopharyngitis. The
incidence of serious adverse events (SAEs) was 3.1%, with
pneumonia the most frequent SAE. Discontinuation from the
study because of a TEAE occurred in 12.1% of treated patients
(9.7% and 19.7% of 1-knee and 2-knee groups, respectively).
Application-site dermatitis was the most frequent AE leading to
discontinuation (6.2% of treated patients, 4.7% and 11.0% of the
1-knee and 2-knee groups, respectively). Of the laboratory tests,
alanine aminotransferase (ALT) was elevated to >3 times the
upper limit of normal in 1% of patients. WOMAC assessments
showed sustained improvement in OA symptoms over 12 months
of treatment.
Conclusions: DSG was well tolerated. The overall rate of treat-
ment discontinuation due to TEAEs was low but higher in the
2-knee group. Mean measures of efﬁcacy showed improvement
in OA symptoms at each assessment over the 12 months of the
open-label study.
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Purpose: A new therapy, based on the intra-articular injec-
tion of autologous conditioned serum (ACS-Orthokine), is used
for osteoarthritis (OA) treatment. ACS is generated by incubat-
ing venous blood with medical grade glass beads. Peripheral
blood leukocytes produce elevated amounts of endogenous anti-
inﬂammatory cytokines such as interleukin-1 receptor antagonist
(IL-1Ra) and growth factors that are recovered in the serum
Methods: This document reports data from an observational,
prospective, cohort study conducted on patients with OA of the
knee. Subjects had completed a six-month randomized, con-
trolled, double-blind trial regarding the efﬁcacy and safety of in-
traarticular injection of ACS-Orthokine compared to Hyaluronan
(HA) and Saline. Previous analysis had conﬁrmed a superior re-
duction in WOMAC, Visual Analogue Scale of Pain (VAS), Global
Patient Assessment (GPA) scores after 6 months. A follow-up
evaluation was conducted to determine whether therapeutic ef-
fects were still present after 2 years.
Results: A total of 310 of the 345 patients who had participated
and ﬁnished the initial study were traced. Of these, 122 had
received additional therapy and were thus re-evaluated sepa-
rately using the last value carried forward method of imputation
(LOCF).
At 2-year follow-up evaluations, there were still statistically sig-
niﬁcant differences between the ACS-Orthokine and both control
groups with regard to WOMAC scores, VAS and GPA. The effect
size was still enormous.
Conclusions: The results demonstrate that treatment with ACS-
Orthokine results in a signiﬁcant therapeutic effect compared
to HA and saline at not only 6 months, but also at 2 years.
Remarkably, the placebo effect seen in patients who received
HA or saline, also persisted for the additional 18 months.
